Michael Rowe

1.1k total citations
17 papers, 275 citations indexed

About

Michael Rowe is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Rowe has authored 17 papers receiving a total of 275 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Economics and Econometrics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Rowe's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Economic and Financial Impacts of Cancer (3 papers). Michael Rowe is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Economic and Financial Impacts of Cancer (3 papers). Michael Rowe collaborates with scholars based in United Kingdom, United States and Switzerland. Michael Rowe's co-authors include Jonathan C. Javitt, Nicholas Tarantino, Erik A. Lippa, Michael B. Nichol, Timothy M.M. Farley, Leonie Eastlake, Toby Talbot, Christopher J. Jones, Anna Olsson‐Brown and Laura Feeney and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Ophthalmology.

In The Last Decade

Michael Rowe

14 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Rowe United Kingdom	5	149	138	111	72	54	17	275
Barny Foot United Kingdom	10	172 1.2×	62 0.4×	43 0.4×	9 0.1×	41 0.8×	18	263
Rushmia Karim United Kingdom	8	267 1.8×	30 0.2×	129 1.2×	10 0.1×	37 0.7×	14	361
Sylvia Nghiem‐Buffet France	15	624 4.2×	32 0.2×	412 3.7×	13 0.2×	14 0.3×	48	660
Joy Kabiru United Kingdom	9	245 1.6×	108 0.8×	137 1.2×	5 0.1×	8 0.1×	13	298
Gábor Tóth Hungary	13	272 1.8×	84 0.6×	262 2.4×	5 0.1×	8 0.1×	50	490
Jonathan H. Tzu United States	13	218 1.5×	27 0.2×	238 2.1×	3 0.0×	10 0.2×	22	354
Mandeep Bindra United Kingdom	9	150 1.0×	23 0.2×	67 0.6×	8 0.1×	20 0.4×	25	228
Ian C. Francis Australia	8	158 1.1×	33 0.2×	68 0.6×	2 0.0×	19 0.4×	18	249
Julia García-Consuegra Spain	6	37 0.2×	52 0.4×	5 0.0×	61 0.8×	13 0.2×	7	315
Tomasz P. Stryjewski United States	11	203 1.4×	18 0.1×	168 1.5×	4 0.1×	1 0.0×	33	352

Countries citing papers authored by Michael Rowe

Since Specialization

Citations

This map shows the geographic impact of Michael Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Rowe more than expected).

Fields of papers citing papers by Michael Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Rowe. The network helps show where Michael Rowe may publish in the future.

Co-authorship network of co-authors of Michael Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Rowe. A scholar is included among the top collaborators of Michael Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Rowe. Michael Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Baxter, Mark, Michael Rowe, Deborah J. Scott, et al.. (2024). UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study. SHILAP Revista de lepidopterología. 3(1). e000459–e000459. 2 indexed citations

Dearden, Helen Clare, Michael Rowe, Deborah J. Scott, et al.. (2024). A United Kingdom prospective, multicentre, observational cohort study investigating tolerance of anti-cancer systemic therapy in the elderly: The TOASTIE study.. Journal of Clinical Oncology. 42(16_suppl). 1521–1521.

Olsson‐Brown, Anna, Mark Baxter, Laura Feeney, et al.. (2022). The association of pre-existing autoimmune disease and immune-related adverse events secondary to immune checkpoint inhibition therapy in a UK multicenter cohort.. Journal of Clinical Oncology. 40(16_suppl). 2522–2522.

Rowe, Michael, et al.. (2021). A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab. Journal of Immunotherapy. 44(4). 175–178. 8 indexed citations

Dearden, Helen Clare, Mark Baxter, Sally Martin, et al.. (2021). Observational study investigating Tolerance Of Anticancer Systemic Therapy In the Elderly (TOASTIE): a protocol. BMJ Open. 11(9). e051104–e051104. 1 indexed citations

Olsson‐Brown, Anna, Mark Baxter, Caroline Dobeson, et al.. (2021). Real-world outcomes in older adults treated with immunotherapy: A United Kingdom multicenter series of 2,049 patients.. Journal of Clinical Oncology. 39(15_suppl). 12026–12026. 5 indexed citations

Rowe, Michael, et al.. (2021). An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks. Journal of Clinical Urology. 15(3). 257–263. 1 indexed citations

McGrane, John, et al.. (2020). Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC). 1–6. 1 indexed citations

Rowe, Michael, Robert H. Liebross, Chad Davis, et al.. (2020). Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine/radiation in borderline resectable (BR) pancreatic cancer: A single-institution experience.. Journal of Clinical Oncology. 38(4_suppl). 718–718. 1 indexed citations

10.

Rowe, Michael, et al.. (2020). The use of intermittent enzalutamide dosing in the treatment of metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). 81–81. 1 indexed citations

11.

Davis, Chad, Robert H. Liebross, Thomas Dugan, et al.. (2016). Neoadjuvant gemcitabine and nab-paclitaxel followed by concurrent capecitabine and radiation efficacy in borderline resectable (BR) pancreatic cancer.. Journal of Clinical Oncology. 34(15_suppl). e15698–e15698. 1 indexed citations

12.

Surbone, Antonella & Michael Rowe. (2015). Clinical oncology and error reduction.

13.

Rowe, Michael, et al.. (2012). A presentation of penile Mondor's disease. International Journal of STD & AIDS. 23(9). 681–682. 1 indexed citations

14.

Javitt, Jonathan C., et al.. (1997). Outcomes of Cataract Extraction with Multifocal Intraocular Lens Implantation. Ophthalmology. 104(4). 589–599. 137 indexed citations

15.

Javitt, Jonathan C., et al.. (1996). Measuring the impact of glaucoma and its treatment on quality of life: The glaucoma disability index. Investigative Ophthalmology & Visual Science. 37(3). 4 indexed citations

16.

Nichol, Michael B., et al.. (1996). The Application of Multiple Quality-of-Life Instruments in Individuals with Mild-to-Moderate Psoriasis. PharmacoEconomics. 10(6). 644–653. 83 indexed citations

17.

Rowe, Michael, et al.. (1990). A retrospective study of 356 midfacial fractures occurring in 225 patients. Journal of Oral and Maxillofacial Surgery. 48(6). 574–578. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact